

The diagnostic value of inflammatory biomarkers in the diagnosis and treatment of influenza B in adults

Ayshah Mammadova,¹ Gunel Jeyranova²

¹Department of Chest Diseases, Faculty of Medicine, Lokman Hekim University Akay Hospital, Ankara; ²Department of Chest Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey

Abstract

Influenza can lead to various complications if not promptly diagnosed and treated. This study aims to assess the predictive value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and Systemic Inflammation Response Index (SIRI), which are derived from routine blood parameters, in diagnosing influenza infection in adults. This study included 130 patients diagnosed with and treated for influenza B from 2022 to 2024. The control group comprised 130 healthy individuals. Influenza B diagnosis was confirmed using rapid antigen kits, and complete blood counts were analyzed via spectrophotometric/impedance methods, with statistical evaluation applied to the results. Among the 130 patients included, 55.3% (n=72) were male. Patients were categorized into two groups: those treated on an outpatient basis and those hospitalized. NLR, PLR, and SIRI values were significantly higher in hospitalized patients than in outpatients (p<0.001 for all parameters). In patients diagnosed with influenza B, NLR [6.11 (1.76-17.15)], PLR [266.66 (138.20-914.28)], and SIRI [3.56 (0.82-10.11)] values were significantly elevated compared to the control group [NLR 1.63 (0.45-2.22); PLR 99.21 (61.84-169.37); SIRI 0.73 (0.45-1.48)] (p<0.001 for all comparisons). The NLR threshold was set at 2.36, achieving 96.7% sensitivity and 100% specificity (p<0.001). The PLR threshold was 153.41 [area under the curve (AUC)=0.988, sensitivity: 93.3%, specificity: 92.9%, p<0.001], and the SIRI threshold was 1.36 (AUC=0.977, sensitivity: 93.1%, specificity: 92.9%, p<0.001), confirming the diagnostic relevance of these parameters. This study demonstrates that NLR, PLR, and SIRI, which are non-invasive, cost-effective, simple, and reproducible biomarkers, provide strong prognostic value in diagnosing and managing adult patients with influenza B, particularly in cases requiring hospitalization.

Key words: influenza B, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, systemic inflammation response index, nasopharyngeal swab.

Correspondence to: Ayshah Mammadova, Department of Chest Diseases, Faculty of Medicine, Lokman Hekim University Akay Hospital, Ankara, Turkey. Tel.: +90 539 395 94 88. E-mail: ayshahmammadova665@gmail.com

Introduction

Influenza is an RNA virus from the Orthomyxoviridae family, with types A and B being particularly pathogenic to humans. Symptoms typically appear abruptly, and the disease is often self-limiting. Influenza infection is generally confined to the upper respiratory tract, presenting with symptoms like fever, sore throat, runny nose, cough, headache, myalgia, joint pain, fatigue, and malaise. In some cases, however, the infection may progress to life-threatening complications, including pneumonia, acute respiratory distress syndrome, and multi-organ failure due to secondary bacterial infections [1]. In the absence of early diagnosis and treatment, complications can also develop in non-respiratory systems [2].

While most influenza cases are diagnosed based on clinical symptoms, this virus may present with clinical profiles similar to those of other respiratory viruses, such as rhinovirus, respiratory syncytial virus (RSV), COVID-19, and parainfluenza. This similarity can make it challenging to distinguish influenza from other respiratory infections. Therefore, obtaining respiratory samples and

performing thorough laboratory testing are essential for accurate diagnosis. The gold-standard laboratory methods for diagnosing influenza include viral culture, reverse transcription polymerase chain reaction (RT-PCR), and serological tests. However, viral culture and serological testing are often too time-consuming for use in outpatient settings. Although RT-PCR provides rapid results, it is costly and requires specialized equipment [3]. In recent years, low-cost rapid antigen tests have been developed, yet these tests have limitations, including a tendency toward false-negative results and low sensitivity [4]. To overcome these limitations, faster molecular assays with high specificity and sensitivity have been developed [5].

The neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the Systemic Inflammation Response Index (SIRI) have been widely used in various studies to evaluate malignancies, pulmonary thromboembolism, ischemic stroke, and rheumatologic and cardiovascular diseases [6,7]. Recently, these parameters have also shown potential as predictive markers in the early diagnosis of infectious diseases, including viral infections. Specifically, a single-center retrospective study demonstrated that NLR, PLR, and mean platelet volume/platelet



ratio are valuable prognostic markers for early diagnosis in children [8]. However, studies on influenza virus infections in adults remain limited [9]. In a study conducted between September 2020 and December 2020, 1330 influenza A cases were compared with 1330 healthy controls, showing that NLR, PLR, platelet count (PLT), and absolute lymphocyte counts were significantly elevated in influenza A cases ($p < 0.001$) [10]. Another study confirmed the prognostic significance of SIRI in cardiovascular diseases [11]. Given this context, our study aims to explore the predictive value of NLR, PLR, and SIRI, derived from routine blood parameters, in diagnosing influenza infection in adults.

Materials and Methods

This retrospective, single-center study was approved by the Ethics Committee for Clinical Research at Gazi University Faculty

of Medicine (decision number 1153, dated 09.07.2024). A total of 178 patients diagnosed with influenza B between July 1, 2022, and July 1, 2024, were screened through our system for inclusion. A total of 48 patients who did not meet the study criteria were excluded, and 130 patients were selected for final analysis (Figure 1). The control group consisted of 130 healthy individuals. Patients aged 18 years and older who tested positive for influenza B through nasopharyngeal swab samples were included in the study. Patients with hematologic disorders, significant liver and kidney dysfunctions, a history of malignancy, pregnancy, or other viral infections (such as influenza A, coronavirus, RSV, adenovirus, and mycoplasma) were excluded. Demographic data (age, sex), smoking status, comorbidities, symptoms, respiratory support needs, antiviral and antibiotic treatments, and complete blood count values of the participants were recorded in patient follow-up forms. Complete blood counts were analyzed in our hospital laboratory using spectrophotometric/impedance methods (Beckman Coulter LH 780 Analyzer;




Figure 1. Flowchart.



Beckman Coulter, Inc., CA, USA). NLR was calculated as the ratio of neutrophil count to lymphocyte count, while PLR was calculated as the ratio of PLT to lymphocyte count. SIRI was calculated using the following formula: (neutrophil count×monocyte count)/lymphocyte count.

Nasopharyngeal swab samples were analyzed in our hospital’s clinical microbiology laboratory using immunochromatographic rapid antigen kits. Swab samples were prepared in a reaction tube and evaluated according to the instructions provided by the kit manufacturer.

Statistical analysis

Statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) version 26.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics for continuous variables were expressed as mean ± standard deviation and median (minimum-maximum), while categorical variables were expressed as number and percentage (%). The distribution of continuous variables was assessed using the Kolmogorov-Smirnov test, and nonparametric tests were employed based on the results. Pearson’s chi-square (χ^2) test was applied to categorical data, Student’s *t*-test to normally distributed continuous data, and the Mann-Whitney U test to non-normally distributed data. The relationships between variables were assessed using Spearman’s correlation coefficient. Cut-off points for NLR, PLR, and SIRI values were determined by receiver operating characteristic (ROC) analysis. A significance level of $\alpha=0.05$ was set for all tests, and differences between groups were considered statistically significant at $p<0.05$.

Results

A total of 130 patients diagnosed with influenza B through nasopharyngeal swab samples were included in the study. The mean age of the study population was 53.36±14.05 years, with 72 patients (55.3%) being male and 58 (44.6%) female. The duration of symptoms before admission ranged from 2 to 7 days, with a median duration of 4 days. Comorbidities were identified in 101 patients (77.7%), while 29 patients (22.3%) had no accompanying comorbidities.

Detailed demographic characteristics are presented in Table 1. During the course of treatment, 57 patients (43.8%) required hospitalization, with 51 (39.2%) admitted to the general ward for an average duration of 4.97±2.83 days. A total of 6 patients (4.6%) required admission to the intensive care unit (ICU), with an average ICU stay of 8.2±5.4 days.

The rate of complications among patients was 23.8% (n=31). Complications included viral pneumonia in 4.6% (n=6) and secondary bacterial pneumonia in 12.3% (n=16) as lower respiratory tract infections. Additionally, 5.4% (n=7) of patients required non-invasive mechanical ventilation, and 1.5% (n=2) required invasive mechanical ventilation.

Evaluation of the patients’ blood parameters showed a median NLR value of 6.11 (1.76-17.15), a median PLR value of 266.66 (138.20-914.28), and a median SIRI value of 3.56 (0.82-10.11). When patients were divided into two groups (outpatients and those requiring hospitalization), the median NLR value for hospitalized patients was 8.61 (4.10-17.15), while it was 5.12 (1.76-6.68) for outpatients, a statistically significant difference ($p<0.001$). Similarly, the median PLR and SIRI values were also

significantly higher in hospitalized patients compared to outpatients. For PLR, median values were 320.80 (157.51-914.28) in hospitalized patients and 230.05 (138.20-324.39) in outpatients; for SIRI, median values were 4.18 (2.12-10.11) and 2.31 (0.82-4.27), respectively ($p<0.001$ for both). Spearman’s correlation analysis revealed positive correlations between hospitalization and NLR ($p<0.001$, $r=0.845$), PLR ($p<0.001$, $r=0.864$), and SIRI ($p<0.001$, $r=0.867$). The control group consisted of 130 healthy individuals with a mean age of 57.57±15.68 years, of whom 81 (62.3%) were male. In patients diagnosed with influenza B, NLR, PLR, and SIRI values were significantly higher compared to the control group ($p<0.001$ for all) (Table 2). Comparisons of laboratory test results and measured values between the two groups are presented in Table 3.

ROC analysis was conducted to determine cut-off values for NLR, PLR, and SIRI in diagnosing influenza. The NLR threshold was determined to be 2.36, with a sensitivity of 96.7% and specificity of 100% ($p<0.001$) (Table 3, Figure 2). For PLR, the threshold was set at 153.41, with an area under the curve (AUC) value of 0.988, sensitivity of 93.3%, and specificity of 92.9% ($p<0.001$) (Table 3, Figure 2). The SIRI threshold was 1.36, with an AUC of 0.977, sensitivity of 93.1%, and specificity of 92.9% ($p<0.001$) (Table 3, Figure 3). These results indicate that NLR, PLR, and SIRI exhibit high accuracy and reliability in diagnosing influenza.

Table 1. Demographic data of patients.

Mean age (standard deviation)	53.36±14.05
Gender, n (%)	
Male	72 (55.3)
Female	58 (44.6)
Comorbid conditions, n (%)	
Cardiovascular disease	63 (48.5)
Diabetes mellitus	41 (31.5)
Chronic obstructive pulmonary disease	33 (25.4)
Asthma	30 (23.0)
Neurological disease	11 (8.5)
Presenting symptoms, n (%)	
Cough	100 (76.9)
Shortness of breath	90 (69.2)
Fatigue	89 (68.5)
Myalgia	73 (56.1)
Fever	55 (42.3)
Headache	46 (35.4)
Sore throat	41 (31.5)
Sputum	35 (26.9)
Chest pain	21 (16.1)
Nausea/vomiting	19 (14.6)
Runny nose	18 (13.8)
Antiviral treatment, n (%)	
Not given	17 (13.1)
Given	113 (86.9)
Antibiotic treatment, n (%)	
Not given	63 (48.5)
Given	67 (51.5)
Patient monitoring, n (%)	
Hospitalized	57 (43.8)
General ward	51 (39.2)
Intensive care	6 (4.6)
Outpatient	73 (56.1)



Table 2. Comparison of laboratory findings between influenza B patients and the control group.

	Influenza B group mean±SD, median (min-max)	Control group mean±SD, median (min-max)	p
Number of cases, n	130	130	1.000
Gender, n (male, %)	72 (55.3)	81 (62.3)	0.751
Age (years)	53.36±14.05	57.57±15.68	0.378
WBC (10 ⁹ /L)	10.53 (5.41-19.83)	7.06 (4.6-10.9)	0.001
Neutrophil (10 ⁹ /L)	8.48 (4.1-16.3)	3.83 (2.4-6.3)	0.001
Lymphocyte (10 ⁹ /L)	1.46 (0.49-2.67)	2.54 (1.6-3.8)	0.001
PLT (10 ⁹ /L)	370 (188-548)	260 (173-336)	0.001
Monocyte (10 ⁹ /L)	0.58 (0.25-0.96)	0.5 (0.4-0.8)	0.357
NLR	6.11 (1.76-17.15)	1.63 (0.45-2.22)	0.001
PLR	266.66 (138.20-914.28)	99.21 (61.84-169.37)	0.001
SIRI	3.56 (0.82-10.11)	0.73 (0.45-1.48)	0.001

SD, standard deviation; WBC, white blood cells; PLT, platelet count; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; SIRI, systemic inflammation response index.

Table 3. Receiver operating characteristic results of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and systemic inflammation response index values in differentiating influenza B and control groups.

	Cut-off value	Sensitivity %	Specificity %	AUC (95%)	p
NLR	2.36	96.7	100	0.992 (0.972-1.000)	0.001
PLR	153.41	93.3	92.9	0.988 (0.962-1.000)	0.001
SIRI	1.36	93.1	92.9	0.977 (0.940-1.000)	0.001

NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; SIRI, systemic inflammation response index.




Figure 2. Receiver operating characteristic (ROC) analysis of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) values for influenza B diagnosis. The figure presents the diagnostic performance and ROC curves of NLR and PLR compared to the control group.




Figure 3. Receiver operating characteristic (ROC) of the Systemic Inflammation Response Index value in influenza B diagnosis. The figure presents the diagnostic performance of SIRI and the ROC curve in comparison with the control group.



Discussion

Seasonal influenza virus causes an infection that emerges primarily in winter months and can spread epidemically [12]. Disease severity varies between years, with symptoms ranging from mild upper respiratory tract infections to severe respiratory failure and other serious complications due to viral replication. Therefore, identifying new prognostic factors is crucial in the management of influenza patients and complications associated with the disease. In this context, biomarkers such as NLR, PLR, and SIRI have been widely studied. Our study found that these indices were significantly elevated in patients diagnosed with influenza B compared to the control group, with positive correlations observed between NLR, PLR, and SIRI values and hospitalization requirements in influenza B patients.

The typical clinical presentation of influenza infection includes sudden-onset fever, headache, muscle pain, and fatigue. In our study, common symptoms in influenza B-positive patients were identified as cough, shortness of breath, fatigue, myalgia, fever, headache, and sore throat. A study by Wansaula *et al.* on severe acute respiratory infections reported similar findings regarding symptom frequency and order, aligning with our results. Similar symptom frequencies have also been reported in influenza-positive cases [13].

NLR is a widely used marker of systemic inflammation that can be quickly and cost-effectively measured through routine complete blood counts. Its use as a biomarker has increased in recent years. A study by Günay *et al.* examined the relationship between NLR and COPD exacerbations, finding NLR averages of 2.59 ± 1.79 in stable COPD patients and 4.28 ± 4.12 during exacerbations [14]. Another study emphasized NLR as a rapid, cost-effective predictor for early sepsis detection [15]. Liberski *et al.* investigated the diagnostic accuracy of NLR for sepsis in ICU admissions [16]. Additionally, NLR was found to be an early marker of poor prognosis in COVID-19 patients, with significantly higher levels in deceased patients compared to survivors [17,18]. A retrospective study on influenza B evaluated 122 patients and 119 controls, finding an NLR of 4.3 (2.92-6.49) in the patient group and 1.68 (1.22-2.07) in the control group, with a significantly elevated NLR in the patient group ($p < 0.001$). This study reported an NLR cut-off of 2.51, with 86.9% sensitivity and 87.4% specificity [9]. In our study, we determined a median NLR of 6.11 (1.76-17.15). Limited mortality data prevented a comprehensive analysis, yet we found that hospitalized patients had an NLR of 8.61 (4.10-17.15) compared to 5.12 (1.76-6.68) in outpatients, a statistically significant difference. When we set the NLR threshold at 2.36, sensitivity was 96.7% and specificity 100%. A recent study comparing NLR in obstructive sleep apnea syndrome (OSAS) patients found significantly higher average NLR in the OSAS group (1.76 ± 0.77) compared to the control group (1.31 ± 0.74) [19]. Similarly, we found significantly higher NLR in the patient group than in controls.

Although the role of platelets in inflammation pathogenesis is still debated, studies have shown that platelets contribute to cytokine production, playing an active role in the inflammatory process alongside their immunomodulatory functions. PLR, calculated as the ratio of PLT to lymphocyte count in routine blood tests, has been investigated in patients with influenza B. One study found that PLR was significantly higher in the patient group compared to controls with a PLR cut-off of 147.99 [9]. In our study, the PLR threshold was set at 153.41 (AUC=0.988, sensitivity: 93.3%, specificity: 92.9%), demonstrating high diagnostic accuracy. Similar studies

have shown that PLR is significantly higher in patient groups than in healthy controls, supporting its diagnostic value [9,10].

During heightened inflammatory states, neutrophils increase as indicators of innate immune response, while lymphocytes, which provide primary immune defense against viruses, decline as disease severity increases. SIRI incorporates both neutrophil and lymphocyte counts, making it an effective marker for evaluating inflammation and immune response. Prior studies have explored SIRI's utility in predicting outcomes in other diseases, including stroke, pancreatitis, and cervical cancer [20-23]. SIRI also demonstrated the highest AUC in predicting peripheral artery disease in diabetic patients [24]. While there are no studies specifically on SIRI in influenza patients, our study shows that SIRI yielded a high AUC and that its levels were significantly elevated in both the patient group and hospitalized patients compared to the control group and outpatients.

Conclusions

Our study suggests that NLR, PLR, and SIRI are significant markers for identifying and managing influenza B in adult patients. These indices were found to be significantly elevated in patients with influenza B compared to the control group, and their levels were positively correlated with the need for hospitalization. Given the high sensitivity and specificity of these markers, they can provide valuable prognostic information for clinicians. However, due to the limited sample size and the lack of comparisons with other viral infections, further studies, including larger multi-center, prospective, randomized controlled trials, are required to validate these findings.

References

1. Frenzen F. Human and Influenza – an Overview. *Pneumologie* 2018;72:207-21. [Article in German].
2. Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. *Influenza Other Respir. Viruses* 2017;11:372-93.
3. Merckx J, Wali R, Schiller I, et al. Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis. *Ann Intern Med* 2017;167:394-409.
4. Hurt AC, Alexander R, Hibbert J, et al. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. *J Clin Virol* 2007;39:132-5.
5. Kim DK, Poudel B. Tools to detect influenza virus. *Yonsei Med J* 2013;54:560-6.
6. Wang RH, Wen WX, Jiang ZP, et al. The clinical value of neutrophil-to-ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage. *Front Immunol* 2023;14:1115031.
7. Chen W, Xin S, Xu B. Value research of NLR, PLR, and RDW in prognostic assessment of patients with colorectal cancer. *J Healthc Eng* 2022;2022:7971415.
8. Zhu R, Chen C, Wang Q, et al. Routine blood parameters are helpful for early identification of influenza infection in children. *BMC Infect Dis* 2020;20:864.
9. Qi JF, Guo ML, Lin L, et al. An exploration of the value of NLR,



- PLR, LMR, and WBC \times CRP for the diagnosis and treatment of influenza B in adults. *Medicine* 2024;103:e37046.
10. Liao Y, Liu C, He W, Wang D. Study on the value of blood biomarkers NLR and PLR in the clinical diagnosis of influenza A virus infection in children. *Clin Lab* 2021;67. Doi: 10.7754/Clin.Lab.2021.210319.
 11. Xia Y, Xia C, Wu L, et al. Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: a 20-year follow-up cohort study of 42,875 US adults. *J Clin Med* 2023;12:1128
 12. National Health Commission of the People's Republic of China; State Administration of Traditional Chinese Medicine. Protocol for diagnosis and treatment of influenza (2019 version). *Chin J Clin Infect Dis* 2019; 12:451-5.
 13. Wansaula Z, Olsen S, Casal M, et al. Surveillance for severe acute respiratory infections in Southern Arizona, 2010-2014. *Influenza Other Respir Viruses* 2016;10:161-9.
 14. Günay E, Ulaşlı SS, Akar O, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. *Inflammation* 2014;37:374-80.
 15. Rehman FU, Khan A, Aziz A, et al. Neutrophils to lymphocyte ratio: earliest and efficacious markers of sepsis. *Cureus* 2020; 12:e10851.
 16. Liberski PS, Szewczyk M, Krzych ŁJ. Haemogram-derived indices for screening and prognostication in critically ill septic shock patients: a case-control study. *Diagnostics* 2020;10:638.
 17. Ulloque-Badaracco JR, Ivan Salas-Tello W, Al-kassab-Córdova A, et al. Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 patients: a systematic review and meta-analysis. *Int J Clin Pract* 2021;75:e14596.
 18. Dursun R, Mermutluoglu C, Aktar F, et al. Which COVID-19 Patients Die in Intensive Care Unit (ICU) in Turkey. *Dicle Med J* 2022;49:85-91.
 19. Diken ÖE, Arslan M. Neutrophil to lymphocyte ratio in obstructive sleep apnea syndrome. *Bozok Tıp Dergisi* 2018;8:1-6.
 20. Choi JL, Li S, Han JY. Platelet function tests: a review of progresses in clinical application. *Biomed Res Int* 2014;2014: 456569.
 21. Zhang Y, Xing Z, Zhou K, Jiang S. The predictive role of systemic inflammation response index (SIRI) in the prognosis of stroke patients. *Clin Interv Aging* 2021;16:1997-2007.
 22. Biyik M, Biyik Z, Asil M, Keskin M. Systemic inflammation response index and systemic immune inflammation index are associated with clinical outcomes in patients with acute pancreatitis? *J Invest Surg* 2022;35:1613-20.
 23. Chao B, Ju X, Zhang L, et al. A novel prognostic marker systemic inflammation response index (SIRI) for operable cervical cancer patients. *Front Oncol* 2020;10:766.
 24. Song Y, Zhao Y, Shu Y, et al. Combination model of neutrophil to high-density lipoprotein ratio and system inflammation response index is more valuable for predicting peripheral arterial disease in type 2 diabetic patients: a cross-sectional study. *Front Endocrinol* 2023;14:1100453.

Received: 9 December 2024; Accepted: 17 March 2025; Early view: 7 April 2025.

Contributions: Ayshan Mammadova, Gunel Jeyranova: design and coordination of the study, data collection, acquisition and interpretation, draft of the article, critical review of the article for important intellectual content and final approval for the version to be published.

Conflict of interest: the authors declare that they have no conflicts of interest.

Ethics approval and consent to participate: this retrospective, single-center study was approved by the Ethics Committee for Clinical Research at Gazi University Faculty of Medicine (decision number 1153, dated 09.07.2024).

Informed consent: since our study is retrospective, written informed consent was not obtained from the patients. However, personal data were anonymized to ensure confidentiality, and no individual data were included.

Patient consent for publication: not applicable.

Availability of data and materials: this single-center retrospective study of 130 patients was carried out by the Department of Chest Diseases at Keçiören Private Hospital. Upon reasonable request, data is available at this address.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

